Skip to main content
SpringerLink
Log in

TAF-Fixkombination bei HIV-HBV-Koinfektion

Endlich klappte die Therapie

Finally the therapy worked

  • FORTBILDUNG . KASUISTIK
  • Published:
MMW - Fortschritte der Medizin Aims and scope

Nebenwirkungen der HIV-Therapie können die Adhärenz beeinträchtigen oder gar zum Abbruch der Therapie führen. Neue, besser verträgliche Substanzen können zu einer erfolgreichen Therapie viel beitragen, wie der folgende komplexe Fall zeigt.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS 2007;21:1273–81

    Article  CAS  PubMed  Google Scholar 

  2. Gallant J, Brunetta J, Crofoot G, et al. Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults. J Acquir Immune Defic Syndr 2016;73:294–298

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Wohl D, Oka S, Clumeck N, et al. Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results. J Acquir Immune Defic Syndr 2016;72:58–64

    Article  CAS  PubMed  Google Scholar 

  4. Ray AS, Fordyce MW and Hitchcock MJ. Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus. Antiviral Res 2016;125:63–70

    Article  CAS  PubMed  Google Scholar 

  5. Deutsche AIDS Gesellschaft. Deutsch-Österreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion - Stand Dezember 2015. Verfügbar unter http://www.daignet.de/site-content/hiv-therapie/leitlinien-1/Deutsch_Osterreichische Leitlinien zur antiretroviralen Therapie der HIV_Infektion.pdf. 2015

Download references

Author information

Authors and Affiliations

  1. Sektion Klinische Infektiologie, Medizinische Klinik und Poliklinik IV, Campus Innenstadt, Klinikum der Universität, Ludwig-Maximilians-Universität München, Pettenkoferstr. 8a, D-80336, München, Deutschland

    Gerardo Ibarra,  Ulrich Seybold &  Johannes R. Bogner

Authors
  1. Gerardo Ibarra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulrich Seybold
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Johannes R. Bogner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gerardo Ibarra.

Additional information

This article is part of a supplement not sponsored by the industry.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ibarra, G., Seybold, U. & Bogner, J.R. Endlich klappte die Therapie. MMW - Fortschritte der Medizin 159 (Suppl 2), 31–33 (2017). https://doi.org/10.1007/s15006-017-9732-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15006-017-9732-0

Keywords

Search

Navigation